Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
A clinical-stage radiopharmaceutical startup with no product revenue just caught the attention of three of pharma's biggest acquirers, and the rights structure hiding inside its Lilly partnership may explain exactly why.
Legend Biotech just posted a quarter that flipped a key narrative for LEGN shareholders, but with a CEO transition underway and the stock still down sharply over the past year, the real…
BioCryst just turned profitable, its HAE drug Orladeyo is minting cash, and a rival's blockbuster acquisition just put the whole rare-disease sector in play. So which pharma giant has the most to…
Replacing $19,000 in annual passive income from a $350,000 portfolio requires a blended yield of roughly 5.4%. That figure is nearly impossible to reach using only large-cap U.S. stocks, where the S&P…
Franklin FTSE International Low Volatility High Dividend Index ETF (NYSEARCA:LVHI) closed Friday at $41 after a quarterly distribution cycle that continues to deliver the income international dividend investors buy this fund for.…
VanEck Pharmaceutical ETF (NYSEARCA:PPH) exists to give investors broad exposure to the global pharmaceutical industry without the binary risk of betting on a single drug pipeline. Right now, that diversification is being…
Most income ETFs draw from a single well: either dividends or options premium. The Amplify CWP International Enhanced Dividend Income ETF (NYSEARCA:IDVO) draws from three simultaneously, and the way it selects holdings…
If a recession were to hit, it’s a foregone conclusion that people won’t stop taking their prescriptions, and they won’t cancel major medical treatments. The same can be said for people who…
AbbVie just rewarded its shareholders again with a dividend. This stock has boosted its payout annually for more than 50 years.
Here is an assessment of how safe the dividend at AbbVie appears to be based on a variety of metrics, including its status as a Dividend Aristocrat.
Fourth-quarter earnings kick off in a big way in 7 to 10 days, and earnings at some of the biggest and best U.S. companies are likely expected to decline for the third…
While many investment professionals suggest short Treasury paper and money markets, healthcare is the place in 2024 for long-term investors looking for growth and income. Demand is growing as the country ages;…
Here are six European Dividend Aristocrats that are the most liquid and well-known for U.S. investors who are looking for income and a degree of diversification away from the American indexes.
For growth and income investors, adding top-quality dividend stocks based in Europe to domestic portfolios may be a solid way to go for the rest of the year. These five top European…
With a recession likely on the way, health care is the place to be in 2023 for long-term investors looking for growth and income. These seven industry leaders offer solid total return…
